Read + Share
Luo J, Li Z, Ge J, Cai S, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment
for unresectable hepatocellular carcinoma: A cost-effectiveness analysis. Cancer 2026;132:e70259.
PMID: 41620851
|
 |
|
Luo J, Li Z, Ge J, Cai S, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment
for unresectable hepatocellular carcinoma: A cost-effectiveness analysis. Cancer 2026;132:e70259.
PMID: 41620851
|
|
|
|